Engineering actin-resistant human DNase I for treatment of cystic fibrosis
about
Micro- and macrorheology of mucusCrystal Structure of a Charge Engineered Human Lysozyme Having Enhanced Bactericidal ActivityLupus and desoxyribonucleaseAmphibian DNases I are characterized by a C-terminal end with a unique, cysteine-rich stretch and by the insertion of a serine residue into the Ca2+-binding siteMagnesium limitation is an environmental trigger of the Pseudomonas aeruginosa biofilm lifestyleEnhanced antimicrobial activity of engineered human lysozymeApoptosis-related functional features of the DNaseI-like family of nucleases.Bi-directional SIFT predicts a subset of activating mutations.Using Pulmozyme DNase treatment in lentiviral vector productionHow cations can assist DNase I in DNA binding and hydrolysis.Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application.LL-37 induces polymerization and bundling of actin and affects actin structure.The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosusRole of magnesium in the failure of rhDNase therapy in patients with cystic fibrosisFunctional and structural characterization of chimeras of a bacterial genotoxin and human type I DNAse.Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.Mutational analysis of human DNase I at the DNA binding interface: implications for DNA recognition, catalysis, and metal ion dependence.Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.Surface-localized spermidine protects the Pseudomonas aeruginosa outer membrane from antibiotic treatment and oxidative stress.Ca2+-dependent activity of human DNase I and its hyperactive variants.Expression and characterization of a DNase I-Fc fusion enzyme.Rabbit DNase I: purification from urine, immunological and proteochemical characterization, nucleotide sequence, expression in tissues, relationships with other mammalian DNases I and phylogenetic analysis.Comparative characterization of rat deoxyribonuclease 1 (Dnase1) and murine deoxyribonuclease 1-like 3 (Dnase1l3).Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection.Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus.Hyperactivity of human DNase I variants. Dependence on the number of positively charged residues and concentration, length, and environment of DNA.Taming hyperactive hDNase I: Stable inducible expression of a hyperactive salt- and actin-resistant variant of human deoxyribonuclease I in CHO cells.A single amino acid substitution of Leu130Ile in snake DNases I contributes to the acquisition of thermal stability.Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
P2860
Q24643968-AFBFCE25-8006-453D-8523-E9CB80F6A6B7Q27667276-41975EB7-7C09-43C5-9D0F-91D79558D220Q28199068-9A997B53-00A2-420A-95E0-90A51E2990CEQ28343588-044ED05E-918C-4EDD-AC9A-6BA28C73A1E8Q28741382-96FA326A-AFC3-409C-A58A-A24F1337BA4FQ30496665-CB4B138A-2B94-417B-BE6B-C2902C222BB9Q30586523-E798AFAB-63B2-4F24-82A2-0FEE7718A488Q33518531-E235679E-1744-4F59-A137-16801512FEA8Q33586289-428E2F5F-5A34-4066-96A7-4B30F22D8AE3Q33761257-141A241A-0574-4C1F-ACF9-2A6E9D872F03Q33806208-18F99A13-653D-41DB-B0EC-344942458C47Q34493979-FB220EFF-EE3A-41FF-A768-7488D98980B3Q34897103-0BFD46DC-CF90-490B-A5F9-558931F660E8Q36237958-2597D348-0502-47BD-B340-837049907598Q36469691-F33519DB-FD8A-4137-ADCA-B2EB13BEE232Q36951268-7372DAE4-FFE7-4DFD-A930-597113A73568Q38338553-A3874FC0-C13D-4B9C-9E80-DD05FCD91470Q40116758-64371F20-1DD5-4212-B2DB-2739D62C9737Q40871295-AAB17D85-F0AC-4951-9614-567CCBE5C5BFQ40927903-DAE07CEE-E791-4307-811E-19837C8A6F75Q41616388-04B0866D-B749-46EE-B850-A27E5741F577Q42159685-5367E8D9-E3EB-4AAD-8040-6697789E0733Q42816497-85F584A3-4B3E-43B4-B3D8-F7B512A43D29Q42930592-F84B5230-D7A9-4C2D-A20E-849C45491CCFQ43685643-1C7E57A7-EE1D-491B-B868-50D8A88C4F08Q46500363-C7C9DA46-8B43-4E68-A6A6-680133448BB3Q47576141-8C2591CD-91E3-401C-93A0-52C1EF55CE49Q48257985-F90F80DF-34E8-4268-9C05-D82E8A6D16ABQ54012100-F0B71DEE-5579-46D5-8E0B-043FFD920ECE
P2860
Engineering actin-resistant human DNase I for treatment of cystic fibrosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineering actin-resistant human DNase I for treatment of cystic fibrosis
@en
Engineering actin-resistant human DNase I for treatment of cystic fibrosis.
@nl
type
label
Engineering actin-resistant human DNase I for treatment of cystic fibrosis
@en
Engineering actin-resistant human DNase I for treatment of cystic fibrosis.
@nl
prefLabel
Engineering actin-resistant human DNase I for treatment of cystic fibrosis
@en
Engineering actin-resistant human DNase I for treatment of cystic fibrosis.
@nl
P2093
P2860
P356
P1476
Engineering actin-resistant human DNase I for treatment of cystic fibrosis
@en
P2093
Lazarus RA
Sinicropi D
P2860
P304
P356
10.1073/PNAS.93.16.8225
P407
P577
1996-08-01T00:00:00Z